Skip to main content

Table 4 Cytoplasmic and membranous expression of the proteins in angiogenic versus non-angiogenic non-small cell lung cancers (NSCLCs)

From: Why some tumours trigger neovascularisation and others don’t: the story thus far

Protein

Intensity percentage score (IPS) of protein expression

P value

Tumour type with higher expression

Angiogenic tumours

Non-angiogenic tumours

HIF1

6.22 ± 0.33

6.00 ± 0.48

0.87

–

HIF2

0.00 ± 0.00

0.00 ± 0.00

Not applicable

–

CA9 cytoplasm

2.38 ± 0.16

3.50 ± 0.23

<0.001

Non-angiogenic

CA9 membrane

4.00 ± 0.40

3.30 ± 0.88

0.62

–

VEGFA

8.83 ± 0.35

7.38 ± 0.78

0.07

–

TYMP

3.20 ± 0.54

2.21 ± 0.32

0.28

–

KDR

94.56 ± 1.64

97.80 ± 1.54

>0.05

–

KDRp34

10.40 ± 0.30

10.55 ± 0.62

0.71

–

FIH

9.10 ± 0.32

10.00 ± 0.47

0.22

–

PHD1

3.74 ± 0.27

4.20 ± 0.48

0.47

–

PHD2

3.50 ± 0.30

2.46 ± 0.53

0.02

Angiogenic

PHD3

2.70 ± 0.09

3.38 ± 0.17

<0.001

Non-angiogenic

DLL4vessels

2.34 ± 0.10

1.53 ± 0.09

<0.001

Angiogenic

TSP stroma

16.98 ± 2.75

2.00 ± 1.74

<0.001

Angiogenic

CXCR4

2.47 ± 0.20

2.34 ± 0.31

0.92

 

EPHB2

7.78 ± 0.27

9.06 ± 0.33

<0.01

Non-angiogenic

EPBH3 cytoplasm

159.3 ± 8.84

202.20 ± 9.95

<0.01

Non-angiogenic

EPBH3 membrane

23.83 ± 7.23

86.51 ± 12.78

<0.001

Non-angiogenic

EPHB4

7.82 ± 0.26

7.40 ± 0.38

0.57

–

SOD1

4.36 ± 0.45

9.39 ± 4.22

0.27

–

BCL2

1.05 ± 0.25

0.68 ± 0.35

0.54

–

FOS

8.05 ± 0.37

5.31 ± 0.55

<0.001

Angiogenic

EGFR

203.40 ± 10.79

166.30 ± 25.74

0.33

–

EGF

18.90 ± 3.03

14.44 ± 4.15

0.72

–

FGF

9.20 ± 0.42

9.72 ± 0.71

0.74

–

BNIP3

6.08 ± 0.36

5.92 ± 0.82

0.88

–

P53

0.28 ± 0.12

2.28 ± 0.56

<0.001

Non-angiogenic

PI3

4.62 ± 0.36

4.92 ± 0.61

0.51

–

SP1

3.70 ± 0.37

3.38 ± 0.55

0.86

–

STAT3

8.78 ± 0.39

7.11 ± 0.79

0.03

Angiogenic

LON

102.50 ± 11.20

134.20 ± 17.10

0.18

–

MEF2D cytoplasm

50.11 ± 4.16

65.67 ± 9.66

0.25

–

MEF2Dmembrane

60.00 ± 7.12

67.50 ± 12.67

0.47

–

JMY

1.84 ± 0.18

2.42 ± 0.31

0.05

Non-angiogenic

TRAP1

4.22 ± 0.28

5.48 ± 0.31

<0.01

Non-angiogenic

GST cytoplasm

236.20 ± 7.16

249.80 ± 11.40

0.23

–

GSTmembrane

28.44 ± 5.52

69.38 ± 14.03

<0.01

Non-angiogenic

NCAM

0.40 ± 0.09

3.92 ± 0.07

<0.001

Non-angiogenic

CHGA

0.08 ± 0.04

0.27 ± 0.14

>0.05

–

SYP

0.12 ± 0.05

0.44 ± 0.15

>0.05

–

  1. All data are presented as mean ± standard error
  2. HIF hypoxia-inducible factor; CA9 carbonic anhydrase 9; VEGFA vascular endothelial growth factor A; TYMP thymidine phosphorylase; KDR vascular endothelial growth factor receptor 2; KDRp34 vascular endothelial growth factor p34; FIH factor-inhibiting HIF; PHD prolyl hydroxylase dehydrogenase; DLL4 Delta-like 4; TSP1 thymidine phosphorylase 1; CXCR4 chemokine (C-X-C motif) receptor 4; EPH ephrin; SOD1 superoxide dismutase 1; BCL2 B cell lymphoma 2; FOS FBJ murine osteosarcoma viral oncogene homolog; EGF epidermal growth factor; EGFR epidermal growth factor receptor; BNIP3 BCL2/adenovirus E1B 19 kDa interacting protein 3; PI3 peptidase inhibitor 3; SP1 Sp1 transcription factor; STAT3 signal transducer and activator of transcription 3; LON Lon protease; MEF2D myocyte enhancer factor 2D; JMY junction-mediating and regulatory protein, p53 cofactor; TRAP1 TNF receptor-associated protein 1; GST glutathione S-transferase; NCAM neural cell adhesion molecule; CHGA chromogranin A; SYP synaptophysin
  3. – Indicates equal expression
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us